Coeptis Therapeutics Achieves Nasdaq Compliance and Looks Towards a Promising Future

Coeptis Therapeutics Regains Nasdaq Compliance

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company specializing in innovative cell therapies, has announced a significant milestone by regaining compliance with Nasdaq's Listing Rule 5550(a)(2). This achievement was confirmed by the Nasdaq Hearings Panel on September 17, 2024, marking an encouraging start to the year for the company.

According to Dave Mehalick, CEO of Coeptis, "We thank the Nasdaq Hearings Panel for approving our request. Regaining compliance with Nasdaq's listing standards is an encouraging start to what we believe will be a transformative year for Coeptis."

The significance of this achievement is rooted in Coeptis's dedication to pioneering cell therapy platforms that aim to tackle cancer, autoimmune conditions, and infectious diseases. This commitment to innovation is underscored by a strong therapeutic portfolio that includes various assets licensed from Deverra Therapeutics. These assets comprise an allogeneic cellular immunotherapy platform as well as DVX201, which is a clinical-stage, unmodified natural killer cell therapy technology. Furthermore, Coeptis is advancing a universal, multi-antigen CAR technology, known as SNAP-CAR, developed in partnership with the University of Pittsburgh, along with other innovative platforms in collaboration with VyGen-Bio and distinguished researchers at the Karolinska Institute.

In line with their strategic growth and operational enhancement, Coeptis has also established a Technology Division. This new division focuses on leveraging advanced technologies to improve efficiency across their operational frameworks. Their initiatives include the incorporation of AI-powered marketing software and robotic process automation tools from NexGenAI Solutions Group, aiming to streamline business processes significantly.

Located in Wexford, PA, Coeptis is unwavering in its commitment to maintaining operations within the stringent framework set by the FDA. This dedication ensures all company activities meet the highest standards of compliance, reflecting its commitment to patient care and adherence to best practices in the biopharmaceutical field.

Moreover, as a forward-looking organization, Coeptis emphasizes the importance of understanding the inherent risks and uncertainties tied to its innovative pursuits. While the leadership team remains optimistic about future ventures, they also recognize the challenges that come with the biotechnology industry, including competition, regulatory hurdles, and the need for continued funding for ongoing clinical trials.

Ultimately, the recent compliance achievement with Nasdaq may serve as a springboard for Coeptis Therapeutics as it forges ahead into 2025. With its robust pipeline of cell therapy initiatives, a commitment to technological advancement, and a focus on patient outcomes, Coeptis is positioned to make a personal impact in the medical field. The company welcomes those interested in their mission and activities to visit their website for further information.